Aerie Pharmaceuticals — Technical Presentation (March 2021)
14 slides from Aerie Pharmaceuticals's technical presentation, Mar 11, 2021
Slide 1: TRPM8: A New Target for the Treatment of Dry Eye
TRPM8: A New Target for the Treatment of Dry Eye David A. Hollander, MD, MBA Chief R&D Officer March 11, 2021 Exhibit 99.1
Slide 2: Important Information
Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety
Slide 3: Majority of Dry Eye Patients Are Untreated
Majority of Dry Eye Patients Are Untreated 1Stonecipher et al. Therapeutics and Clinical Risk Management 2013 Over 30 million individuals in the US alone suffer from dry eye, yet less than 10% are treated. Dry eye has significant impact on reading, driving at night, workplace productivity and overal
Slide 4: Unmet Need for a Novel MOA that Addresses Symptoms and Signs of Dry Eye
Unmet Need for a Novel MOA that Addresses Symptoms and Signs of Dry Eye Pharmaceutical treatments approved today for dry eye are anti-inflammatories. These anti-inflammatory therapies are often associated with poor compliance secondary to delayed onset or poor tolerability. With the evolving underst
Slide 5: The Innervation of the Ocular Surface
The Innervation of the Ocular Surface Health of the ocular surface is maintained by the integrated lacrimal functional unit (LFU).1 Distinct types of trigeminal ganglion neurons innervate the ocular surface and are specialized for detection of physical (mechanical, thermal) and chemical stimuli. Dis
Slide 6: TRPM8 as a Target for Dry Eye
TRPM8 as a Target for Dry Eye TRPM8 Cold Thermoreceptors TRPM8 channels detect drops in corneal temperature associated with evaporation on the ocular surface TRPM8 nerve terminals exhibit tonic, spontaneous activity which rapidly increase in activity with cooling.1-2 TRPM8 channels modulate basal te
Slide 7: AR-15512: A Selective TRPM8 Agonist
AR-15512: A Selective TRPM8 Agonist AR-15512 (AVX-012) is a potent and highly-selective TRPM8 agonist designed as a potential treatment for DED. Other known cooling agents have lower potency and cross-activate other channels leading to pain and inflammation. In vitro, ex vivo, and in vivo preclinica
Slide 8: Phase 2a Study
Phase 2a Study Phase 2a Study Study Parts Objectives Treatment Groups N Part A Safety 0.0007% AVX-012 TID 0.0014% AVX-012 TID Vehicle TID 24 Part B Safety Efficacy AVX-012 (0.0007% or 0.0014%) BID Vehicle BID AVX-012 (0.0007% or 0.0014%) TID Vehicle TID 109 The dose of AVX-012 ophthalmic solution fo
Slide 9: Phase 2a: Study Design
Phase 2a: Study Design aerie Study part A Study part B Screening Screening (day -5 to day 0) (day-5 to day 0) i L Treatment period Treatment period (day 1 to day learly termination) (day 1 to day 28/early termination) 0.0007% AVX-012 TID, 0.0014% AVX-012 TID, vehicle TID AVX-012 (0.0007% or 0.0014%)
Slide 10: Phase 2a Results: Symptoms
Phase 2a Results: Symptoms p=0.021 h Symptoms: SANDE Score Percentage of patients improving ≥20 score h Primary Endpoint: % of subjects achieving >20 improvement in SANDE questionnaire Continued improvement in symptoms observed at each visit over 28 days. Statistical significance achieved for sympto
Slide 11: Phase 2a Results: Signs
Data on File Phase 2a Results: Signs Continued improvement in signs (tear production) observed at each visit over 28 days. Statistical significance achieved for tear production (% subjects with > 3 mm improvement) with 0.0014% BID dosing. Sign: Schirmer Evaluation Percentage of patients improving ≥3
Slide 12: Phase 2a: Safety
Phase 2a: Safety Treatment-Related Adverse Events by Organ Class and Preferred Terms – Part B AR-15512 0.0014% BID n=28 Vehicle BID n=24 AR-15512 0.0014% TID n=30 Vehicle TID n=27 Eye Disorders Eye pruritis Ocular hyperemia Eye Pruritis/ Vision blurred Foreign body sensation Eye irritation Foreign b
Slide 13: AR-15512 Phase 2b: COMET-1
AR-15512 Phase 2b: COMET-1 COMET-1 “Cold-Thermoreceptor Modulation as an Effective Treatment for DED” Objective: To evaluate the safety, tolerability and efficacy of 2 doses (0.0014% and 0.003%) of topical ophthalmic AR-15512 compared to vehicle administered twice daily in subjected with DED Design:
Slide 14: AR-15512: A TRPM8 Agonist for the Treatment of Dry Eye
AR-15512: A TRPM8 Agonist for the Treatment of Dry Eye AR-15512 is a selective agonist of the TRPM8 cold thermoreceptor with potential to improve both the symptoms and signs of DED. A novel MOA (different from currently approved anti-inflammatories) designed to produce a cooling sensation to relieve
Aerie Pharmaceuticals — Technical Presentation (March 2021) on 6ix